The category of Vmn2r15 Inhibitors represents a collection of chemical compounds that, while not directly inhibiting Vmn2r15, have the capacity to modulate signaling pathways and cellular processes indirectly associated with the function of Vmn2r15. These inhibitors operate through diverse mechanisms, such as the inhibition of protein kinases, modulation of calcium signaling, and interference with specific signaling cascades. By targeting these mechanisms, the compounds can influence the cellular context in which Vmn2r15 operates, thereby offering indirect means to study and potentially modulate the activity of Vmn2r15.
This indirect approach to modulation highlights the complex interplay of cellular signaling pathways, where alterations in one part of the network can impact the function of proteins such as Vmn2r15. The selected compounds illustrate the potential for chemical intervention in these pathways, providing tools for exploring the roles of Vmn2r15 in signal transduction and cellular communication. Through such exploration, these inhibitors not only contribute to our understanding of Vmn2r15's biological functions but also underscore the broader principles of signal transduction and cellular regulation. This approach emphasizes the strategic use of chemical compounds to dissect the intricate signaling networks within cells, facilitating insights into how specific proteins, such as Vmn2r15, fit into the larger puzzle of cellular communication and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Inhibits protein synthesis, potentially affecting the expression levels and function of proteins involved in Vmn2r15-related signaling pathways. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $136.00 | 20 | |
Inhibits Ca2+/calmodulin-dependent protein kinase II (CaMKII), possibly affecting calcium signaling pathways linked to Vmn2r15 activity. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Potent inhibitor of protein kinase C (PKC), which could modulate signaling pathways that intersect with Vmn2r15's signaling mechanisms. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor, increases cytosolic calcium concentration, potentially influencing calcium-dependent signaling pathways related to Vmn2r15. | ||||||
U-73343 | 142878-12-4 | sc-201422 sc-201422A | 5 mg 25 mg | $93.00 $350.00 | 17 | |
Inactive analogue of U73122, used as a control, affecting phospholipase C signaling indirectly related to Vmn2r15's function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Specific inhibitor of protein kinase C (PKC), which could alter signaling pathways intersecting with Vmn2r15's activity. | ||||||
Xestospongin C | 88903-69-9 | sc-201505 | 50 µg | $510.00 | 14 | |
Inhibits IP3 receptor, affecting calcium signaling and potentially influencing signaling pathways that Vmn2r15 is part of. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
Inhibits PKC, potentially affecting GPCR-mediated signaling pathways relevant to Vmn2r15's signaling mechanisms. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
p38 MAPK inhibitor, potentially affecting stress and inflammatory signaling pathways that could intersect with Vmn2r15's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, potentially affecting AKT signaling pathways that could intersect with signaling mechanisms involving Vmn2r15. | ||||||